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We report on an enzymatic-chemical method for the 
specific preparation of L-amino acid-derived q u in o x a -  
linols suitable for the sensitive estim ation o f  I3C- or 
^ • la b e l enrichm ent by gas chrom atography-m a ss  
spectrometry: Amino acid fractions are isolated fro m  
physiological fluids by ion-exchange ch ro m a to g ra p h y *  
The compound of in terest is converted to  th e  c o r r e ­
sponding 2-oxo acid by treatm ent w ith  an L -am ino a c id  
dehydrogenase of the desired specificity. Reaction of 
the 2-oxo acid with o*phenylenedi amine y ie ld s  th e
quinoxaline derivative. Isotopic label enrichm ent is
then determ ined by gas chrom atographic-m ass spec­
trom etric analysis of the O-trimethylsilyl derivative 
using an ammonia-chemical ionization mode and se­
lected ion monitoring of the qua si-molecular ions 
fMH] * and [MH 4* nV {n = num ber of labeled positions). 
Details for application of various generally available 
L -am in o  acid dehydrogenases (L-ala DH, L-glu DH, L- 
leu DH, L-phe DH) are presented. The method was 
used, e.g., for serum analysis in in vivo studies on the 
decarboxylation rates of branched-chain l-[1-13C]-
amino acids, t  1985 Academic Press, Inc,
In recent years, increasing availability of stable iso­
tope labeled substrates and instrumentation for mea­
surement of isotope enrichment in metabolites has 
greatly stimulated in vivo  approaches for the study of 
metabolic fluxes in man (1).
In numerous studies, stable isotope labeled L-amino 
acids have been used as substrates. To account for the 
dilution of isotope label in the L-amino acid and possi­
bly in the derived 2-oxo acid pools of the body, gas
chromatographic-mass spectrometric analyses (GC- 
MS) of the label enrichment in the protein-bound and/ 
or free compound(s) of interest must be performed (1).
Among the numerous derivatization procedures suit­
able for gas chromatographic separation of L-amino 
acids (see (2,3) for reviews) and subsequent analysis 
by MS, two methods have been generally applied: sily- 
lation (4-7) in combination with electron-impact ion­
ization (El)2 and esterification followed by N-acylation 
(8-14) in combination with either chemical ionization 
(Cl) or El.
In contrast to the variety of methods applied for GC- 
MS analysis of stable isotope labeled amino acids, there 
is a method of choice for the derived 2-oxo acids: 2-Oxo 
acids readiLy form quinoxaline derivatives by reaction 
with o-phenylenediamine (15). The O-TMS quinoxali- 
nol derivatives are stable and exhibit favorable gas 
chromatographic properties, thus facilitating the sepa­
ration of complex mixtures. Using Cl, only minor frag­
mentation occurs which is a prerequisite for sensitive 
MS determination of label enrichment (16-19).
When we started studies on the effect of oral loads of
l-13C-labeled branched-chain L-amino acids on serum 
kinetics and whole-body oxidation rates of branched- 
chain compounds in healthy persons and patients with 
maple syrup urine disease, we found it rather unfavor­
able to run different GC-MS programs for the determi­
nation of 13C-label enrichment in serum L-amino and
the derived 2-oxo acids. We therefore examined meth­
ods for the conversion of L-amino acids into quinoxaline 
derivatives.
Chemical procedures have been described (20). They 
are, however, unspecific and rather complicated. Thus,
'P re lim inary  results have been presented a t the 1993 Annual 
Meeting of the Arbeitsgemeinschaft Stabile Isotope in Kiel, Ger­
many.
0003*2697/95 $12.00
Copyright £  1995 by Academic Press, Inc.
All rights of reproduction in any form reserved.
2 Abbreviations used: El, electron-impact ionization; Cl, chemical 
ionization; TMS, trimethylsilyl; TAP, trifluoroacetyl »-propyl; MPE,
mole percentage enrichment; SIM, selected ion monitoring.
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we studied the use of L-amino acid dehydrogenases for 
the preparation of quinoxaline derivatives from l- 
amino acids via their corresponding 2-oxo acids.
In the present communication we report on the appli­
cation of generally available L-amino acid dehydroge­
nases for the specific enzymatic-chemical synthesis of 
quinoxaline derivatives of L-alanine, branched-chain l- 
amino acids, L-glutamate, and L-phenylalanine from 
physiological fluids. Usefulness of the method for GC- 
MS measurement of 2H- and 13C-label enrichment is 
demonstrated, e.g., by serum analysis after oral loading 
with branched-chain L-[13C]amino acids.
MATERIALS AND METHODS
Chemicals
Unless otherwise noted, all chemicals and reagents 
were purchased in the highest available purity from 
Merck (Darmstadt, Germany) or Sigma Chemie (Mu­
nich, Germany). Coenzymes, L-alanine dehydrogenase 
(EC 1.4.1,1; from Bacillus subtilis), and L-glutamic acid 
dehydrogenase (EC 1.4.1.3; from beef liver) were from 
Boehringer, (Mannheim, Germany), l - leucine dehydro­
genase (EC 1.4.1.9; from Bacillus sp.) from Sigma, and 
L-phenylalanine dehydrogenase (EC 1.4.1.-; from Rho- 
dococcus sp.) from Calbiochem (Bad Soden, Germany).
For convenience, L-amino acid dehydrogenase activi­
ties were determined spectrophotometrically at 25°C in 
glycine/NaOH buffer (0.25 mol/liter, pH 10.0) con­
taining EDTA (1 mmol/liter), NAD+ (4 mmol/liter), and
10 mmol/liter of the appropriate L-amino acid sub­
strate. For assay of L-glutamic acid dehydrogenase 
from beef liver, the mixture additionally contained 
ADP (2 mmol/liter) and L-glutamate concentration was 
20 mmol/liter. One unit is defined as the amount of 
enzyme activity reducing 1 pmo\ NAD+ per minute un­
der the above assay conditions,
L-[l-10C]Leucine (1“13C, 99%) was obtained from 
Campro Scientific (Emmerich, Germany), l-[1-13C]- 
valine (1-13C, 99%) and L-[13C]phenylalanine (ring-13C6) 
99%) were from Promochem (Wesel, Germany) and 
checked for purity and isotope content by automatic 
amino acid and GC-MS analysis as given below. L-[U- 
HC]Glutamic acid (10.4 GBq/mmol), L-[l-14C]leucine 
(2.2 GBq/mmol), and L-[l-14C]valine (2.0 GBq/mmol) 
were obtained from NEN (Dreieich, Germany), l-[1- 
14C]alanine (1.85 GBq/mmol) and L-[l-HC]phenyl- 
alanine (2.18 GBq/mmol) were from Amersham
Buchler (Braunschweig, Germany), and l-14C-labeled 
L-isoleucine (14.1 MBq/mmol) was synthesized as de­
tailed previously (21).
Pure quinoxaline derivatives of L-amino acids were 
prepared from the corresponding 2-oxo acids according 
to Nielsen (22) as described (23).
Preparation o f 13C-Enriched Controls
Control serum (Precinorm from Boehringer) was 
used to prepare equimolar stock solutions (0.3 mmol/ 
liter) with pure natural L-phenylalanine or L-leucine
and pure L-[ring-13C6]phenylalanine (ring-13C, 99%) or 
L-[l-13C]leucine (1-13C, 99%). Appropriate volumes of 
the stock solutions were mixed to give a calculated 1- 
13C-label enrichment between 2 and 30% as given un­
der Results. Samples of the stock solutions and the
mixtures were then analyzed for label enrichment as 
detailed below.
In Vivo Loading Studies
After an overnight fast, a healthy volunteer and a 
patient with maple syrup urine disease (male, 14 years) 
orally ingested L-[l-13C]valine or L-[l-l3C]leucine (38 
/¿mol/kg body wt), Blood samples were taken from a 
cannula inserted into the basilic vein at 30 min and 
just before the load (control values) and further every 
15 min over a period of 3 h.
Serum samples were analyzed for concentration and
13C-label enrichment in branched-chain compounds as 
described below.
Analysis of Amino and 2-Oxo Acids
For amino acid analysis, serum samples were mixed 
with an equal volume of Li-citrate buffer (Li+, 0.1 mol/ 
liter, pH 2.2) and protein was removed by ultrafiltra­
tion (centrifreefrom Amicon, Witten, Germany). Amino 
acids were then determined on an automatic amino 
acid analyzer (LC 5001; Eppendorf-Biotronik, Maintal, 
Germany) (21).
The procedure for branched-chain 2-oxo acid and 
phenylpyruvate analysis has been described previously 
in detail (23). In short, 2-oxo acids in deproteinized 
serum samples were reacted with o-phenylenediamine 
to yield the quinoxaline derivatives. After solid-phase 
extraction on a 1-ml Ci8 column (from Baker, GroB- 
Gerau, Germany), the quinoxaline derivatives were
quantified using reversed-phase high-performance liq­
uid chromatography and fluorescent detection, 2-Oxo- 
hexanoate was used as an internal standard, and 
blanks and standard solutions were run in parallel.
For analysis of the more hydrophilic quinoxaline 
derivatives of pyruvate and 2-oxoglutarate, the solid- 
phase extraction procedure and the conditions of re­
versed-phase HPLC analysis had to be modified as 
follows: After reaction with o-phenylenediamine, the 
reaction mixture (1 ml) was applied onto a 1-ml Cl8-
SPE column. After successive washes with 1 ml water 
and 1 ml methanol:water (1:4, v/v), the quinoxaline 
derivatives were eluted with 0.5 ml CH3CN:water 
(30%, v/v). HPLC analysis was carried out using 20% 
CH3CN (v/v) under isocratic conditions.
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Preparation of Quinoxaline Derivatives from L-Amino
Acids
For synthesis of quinoxaline derivatives of L-amino 
acids other than glutamate, serum (0.2 ml) was mixed 
with 5-sulfosalicylic acid (0.5 ml, 5%, w/v). After cen­
trifugation (10 000#, 5 min, 4°C), amino acids were 
separated from preformed 2-oxo acids by SPE on a 1- 
ml sulfonic acid SPE column (from Baker) prewashed 
with 1 ml methanol and 1 ml water. Acid extract (0.5 
ml) was applied to the column followed by two washes 
with 1 ml water. Amino acids were then eluted with 
0.5 ml NH4OH (2 mol/liter). After addition of 0.02 ml 
NaOH (2 mol/liter), the solution was evaporated to dry­
ness under a stream of nitrogen.
In the latter procedure, hydrolysis of glutamine oc­
curs causing interference with the determination of la­
bel in glutamate. Therefore, glutamate was first sepa­
rated from glutamine as follows: 0.2 ml serum was 
mixed with cold ( - 20°C) 75% ethanol (v/v, 0.8 ml) and 
precipitated protein removed by centrifugation. Super­
natant (0.8 ml) was applied onto a 1-ml anion-exchange 
SPE column (quarternary amine, acetate form; from 
Baker) and glutamine (and other amino acids) removed 
by two washes with 1 ml water. The adsorbed acidic 
amino acids were eluted with 0.5 ml acetic acid (2 mol/ 
liter). When preformed 2-oxo acids in the acid eluate 
were initially decarboxylated by treatment with hydro­
gen peroxide, problems occurred with the HPLC analy­
sis of quinoxaline derivatives. Therefore, interfering 
compounds were removed from the acid eluate by the 
cation-exchange chromatographic procedure described 
above.
For treatment with L-amino acid dehydrogenases,
the dry residue was dissolved in 0.1 ml HC1 (0,4 mol/ 
liter) and 0.15 ml conversion mixture was added con­
taining glycine/NaOH buffer (0.33 mol/liter, pH 10.0),
NAD+ (13 mmol/liter), and enzyme activity as appro­
priate. Final enzyme activities in mmol x min~J x
liter“1 amounted to L-alanine dehydrogenase, 1.7; l- 
glutamic acid dehydrogenase, 1.5; L-leucine dehydroge­
nase, 0.5; and L-phenylalanine dehydrogenase, 0.07,
After 30 min of incubation at 37°C, 0.5 ml HCIO4 (0.8 
mol/liter) was added and enzyme protein removed by
centrifugation (10 000 ,^ 5 min, 4°C). The L-amino acid-
derived 2-oxo acids in the acid supernatant (0.5 ml) 
were then reacted with o-phenylenediamine (10 g/liter 
in 2 mol HCl/liter; 0.5 ml; 30 min at 45°C) and the 
resulting quinoxaline derivatives purified by solid- 
phase extraction as given above.
Determination of Recovery and Yield
SPE recovery of amino acids was determined by com- gen
was removed by addition of 0.02 ml NaOH (2 mol/liter) 
and evaporation to dryness.
Due to the vast excess of glycine in the incubation 
mixture, the extent of enzymatic conversion of L-amino 
acids was not feasible by automatic amino acid analy­
sis. Therefore, incubation mixtures were spiked with 
trace amounts of 14C«labeled L-amino acids (1.6 kBq/ 
ml). After enzymatic conversion and acidification, the 
label in 2-oxo [14C] acids was completely removed as 
14C02 by treatment with H20 2 (30%, w/w, 0,1 ml) (24) 
and subsequent evaporation to dryness. The residue 
was dissolved in 0.2 ml water. Radioactivity in the re- 
maining [u C]amino acids was determined by liquid 
scintillation counting. As controls, parallel samples 
were run in the absence of enzyme activity.
Final yields of quinoxaline derivatives were deter­
mined by high-performance liquid chromatographic 
analysis using pure quinoxaline derivatives for stan­
dardization (23).
Gas Chromatography of Quinoxalinol Derivatives
Prior to use, the quinoxaline derivative containing 
SPE eluates were evaporated to dryness under a 
stream of nitrogen.
Samples were then dissolved in 0.04 ml of a mixture 
of BSTFA and pyridine (1:1, v/v) and allowed to stand 
at ambient temperature for at least 15 min to form the 
O-TMS derivatives of the quinoxalinols. The solution 
(0.2 to 0.5 /¿I) was injected into a splitless/split injector 
of a Model 3000 gas chromatograph (Varian, Darm­
stadt, Germany) equipped with a permabond OV-1 col­
umn (25 m, 0.32 mm i.d., 0.35 /¿m film thickness; from 
Macherey-Nagel, Düren, Germany) and directly con­
nected to an INCOS 50 mass spectrometer (Finnigan 
MAT, Bremen, Germany). Helium was used as carrier 
gas. Splitless time was 0.7 min, and split was 20:1. In
general, the following temperature program was used: 
injector and transfer line to MS, 250°C; column oven
120°C initial and then increased at 10°C/min to 200°C 
and at 30°C/min to 280°C and held for 3 min.
Preparation of N-Trifluoroacety I n-Propyl (TAP) 
Derivatives
Solutions of L-amino acids (50 nmol each) were evap­
orated to dryness. For propylation, 0.5 ml propanolic
acid (2 mol/liter; prepared according to 
(25) from rc-propanol and acetylchloride) was added. 
The mixture was heated at 60°C for 60 min in a sealed 
flask and thereafter evaporated to dryness under a
stream of N*. The residue was dissolved in 0.2 ml di-
^  i  • • •
• è  I k è  I * I < I f _
solvent removed under nitro-
and 100 ptl
paring the amount of amino acids in the original serum 
sample and the NH4OH eluate of the cation-exchange 
SPE. Prior to automatic amino acid analysis, ammonia
trifluoroacetic anhydride and subsequent equilibration 
with N2, the sample was allowed to stand in a closed 
vial at ambient temperature overnight. The mixture
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was evaporated under a stream of nitrogen, 0.2 ml di- 
chloromethane added, and evaporation repeated, Fi­
nally, the residue was dissolved in 0.2 ml dichlorometh- 
ane and 0.5 ¡A of the solution analyzed by GC-MS 
using ammonia-CI and the program described above.
Mass Spectrometry
El spectra were recorded at 70 eV ionization energy 
and an ion source temperature of 200°C. For Cl, ammo­
nia was used as reactant gas and the ion source was 
held at 70°C.
In the Cl mode, the mass spectra of the 0-TMS quin- 
oxalinol derivatives showed only minor fragmentation. 
With the derivatives of natural L-ala, L-glu, L-ile, L-leu, 
L-phe, and L-val (and derived 2-oxo acids), ion intensity 
was concentrated on the quasi-molecular ions [MH] + 
appearing at mlz 233, 249, 275, 275, 309, and 263, re­
spectively.
Ion intensity of the TAP derivatives of L-phe was
concentrated on the quasi-molecular ion [MH]+ ap­
pearing at mlz 321.
Analysis o f 13C-Enrichment
Ammonia-CI was generally applied. For determina­
tion of label enrichment in the O-TMS quinoxalinol 
derivative of L-[ring-13C6]phenylalanine, the ratio of ion 
intensity at mlz 315 to mlz 309 was measured by se­
lected ion monitoring. The TAP derivative was ana­
lyzed at mlz 327 and mlz 321.
For measurement of l- l3C-label enrichment in serum 
samples after oral loading with L-[1-13C] valine, the ra­
tio of ion intensity at mlz 264 to mlz 263 was monitored. 
For analysis of l-[1-13C]leucine and the corresponding
2-oxo acid, the ratio of ion intensity at mlz 276 to mlz 
275 was determined.
Calculations
The mole percentage enrichment (MPE) of 13C-la- 
beled branched-chain compounds in authentic serum 
samples was calculated from the ion abundance ratios 
R in postload samples and the natural abundance ratio 
R 0 as determined in the appropriate control samples. 
Ratios were normalized to an ion abundance of 1 at 
mlz 263 and mlz 275 for the O-TMS quinoxalinol deriv­
atives of L-[13C]valine/3-methyl-2-oxo[13C]butanoate 
and L-[13C]leucine/4-methyl-2-oxo[13C]pentanoate, re­
spectively. MPR was then calculated (1) as MPE =
(R -  R 0)I{1 + (R -  i?o)}*100.
With L -[ring-13C e]phenylalanine and l- [1 ~ 13C] leucine
spiked control sera, the stock solutions containing nat­
ural L-phenylalanine or L-leucine were used for the de­
termination of the natural isotope abundance CR0 
value) by GC-MS of the O-TMS quinoxalinol and TAP 
derivatives.
In general, results are presented as means ± SD 
(number of determinations in parentheses). Linear re­
gression analysis (least-square method) was used for 
statistical evaluation.
RESULTS
Efficiency of Quinoxaline Synthesis
Specificity and yield of the enzymic-chemical proce­
dure for conversion of serum L-amino acids into the 
corresponding quinoxaline derivatives were carefully 
checked for each of the L-amino acid dehydrogenases 
applied in this study. The compiled data are presented 
in Table 1.
The amino acids of interest were separated from 2- 
oxo acids by cation-exchange chromatography and re­
covered in >90% yield. With glutamate, recovery was 
somewhat lower due to necessity of prior removal of 
glutamine (and most other amino acids) by anion-ex­
change chromatography. When the latter procedure 
was examined with L-glutamine-enriched (2 mmol/li­
ter) control sera, less than 0.5% of glutamine appeared 
in the glutamate fraction.
For enzyme treatment, incubation conditions were 
adjusted to achieve a reasonable yield of the desired 2- 
oxo acid and a minimum of interferences. As studied 
with l4C-labeled tracers, the time course of enzymatic 
conversion of L-amino acids was essentially hyperbolic. 
No significant amounts of interfering quinoxaline de­
rivatives were detected by HPLC analysis. In incuba­
tions with L-phenylalanine dehydrogenase, however, 
minor amounts of the quinoxaline derivative of L-leu­
cine accumulated (cf. Table 1). Furthermore, some phe- 
nylpyruvate was reaminated during prolonged incuba­
tion, most likely due to the, though slow, oxidative 
deamination of L-leucine and production of ammonia 
(cf. Fig. 1). Under our experimental conditions, effi­
ciency of the enzymatic conversion was generally >70%
(Table 1).
After derivatization of 2-oxo acids with o-phenylene- 
diamine and purification by RP-SPE, variable yields of 
quinoxaline derivatives were obtained, ranging from 
about 3 to about 22 nmol/sample with the derivatives 
of L-glutamate and L-alanine, respectively (Table 1). 
The final yield primarily depended on the concentra­
tion of the L-amino acid in the serum sample and on the 
stability of the derived 2-oxo acid in the derivatization 
mixture. In all cases, however, the amount of quinoxa­
line derivative was more than sufficient for sensitive 
GC-MS analysis which required about 0.02 nmol.
G C -M S Analysis of [13C] Quinoxaline Derivatives
Applicability of the above enzymic-chemical proce­
dure for measurement of isotope enrichment in individ­
ual L-amino acids was first tested using variably
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TABLE 1
Recovery and Yield of Selective Enzymatic-Chemical Synthesis of Quinoxaline Derivatives
of Amino Acids from Serum Samples
Serum 
L-amino acid
SPE recovery 
<%)
Enzyme
treatm ent
Enzymatic 
conversion (%)
Final yield of Qx 
derivatives
(nmol/0.2 ml 
serum)
Rel yield of Qx derivatives 
(% of amino acid in serum )
Alanine 91.0 ± 7.2 (12) Ala-DH 84.9 ± 9.0 (8) 21.7 ± 4.3 (8) 22.3 ±  6.1 (8)
G lutam ate 82.9 ± 5.5a (6) Glu-DH 75.2 ± 8.4 (6) 3.1 ± 1.3 (6) 22.4 ±  6.3 (6)
Isoleucine
Leucine
Valine
93.3 ± 3.9 (12) 
93.6 ± 3 .1  (12) 
93.2 ± 3 .3  (12)
Leu-DH
85.9 ± 4.1 (7) 
88.7 ± 1.5 (7) 
71.6 ± 7.2 (7)
4.0 ± 1.5 (73) 
10.5 ± 3.4 (73) 
8.5 ± 3.4 (73)
33.0 ± 9.0 (73) 
36.6 z  8.6 (73) 
18.2 ± 6.0 (73)
Phenylalanine
Leucine
90.5 ±  3.0 (12)
93.6 ± 3 .1  (12) Phe-DIi
84.3 ± 4.9(12) 
nd
3.9 ± 0.5 (12) 
0.09 ± 0.06 (12)
15.8 ± 0.9 (12) 
0.2 ± 0.1 (12)
Note. Amino acid fractions were isolated by deproteinization and ion-exchange chromatography (SPE recovery). Individual compounds 
were converted to the corresponding 2-oxo acids by treatm ent with L-araino acid dehydrogenases (DH) as indicated (enzymatic conversion). 
Quinoxaline {Qx) derivatives were formed by reaction with o-phenylenediamine and purified by reversed-phase chromatography (final yield). 
See M aterials and Methods for details. Results are means ± SD with the number of determinations in parentheses; nd, not determ ined. 
a Includes anion- and cation-exchange SPE.
L-[rmg-13C6]phenylalamne-enriched (0-99%, nine sam­
ples) control sera. The results in Fig. 2 show a good 
agreement of the calculated isotope enrichment and 
the data as obtained by GC-MS analysis of the O-TMS 
quinoxalinol derivatives. Noteworthy, a quite compara­
ble correlation between predicted and measured l3C 
enrichment was obtained, when the A/'-trifluoroacetyl 
n-propyl derivatives of L-[13C]phenylalanine (samples 
in duplicate) were used for GC-MS analysis (linear 
regression analysis: y = l.OO&x -f 0.139; n = 18, R -  
0.999; cf. legend to Fig, 2). Similar results were also
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FIG . 1. Time course of the enzymatic conversion of L-phenylalanine 
in an  amino acid fraction from hum an serum. Amino acids were 
isolated by deproteinization and cation-exchange chromatography 
and tracer doses of L-[l-14C]phenylalanine were added. Conversion 
of phe to the corresponding 2-oxo acid was achieved by treatm ent 
w ith  L-phenylalanine dehydrogenase (glycine/NaOH, 0.2 mol/liter, 
pH 10.0; NAD*, 8 mmol/liter; 37°C; enzyme activity as indicated). 
The reaction was monitored by m easuring the am ount of H202-stable
lMC)phe rem aining in the incubation m ixture. Controls were run in 
the absence of enzyme activity. For further details see M aterials and 
Methods.
achieved when O-TMS 2-butyl(3-methylM13C]quin- 
oxalinols were prepared from samples correspondingly 
enriched in L-[l-13C]leucine (data not shown).
The method was then applied successfully to serum 
analyses. Representative GC-MS traces of L-alanine 
and L-phenylalanine O-TMS derivatives as prepared 
from human serum samples are shown in Fig. 3. In
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FIG . 2. Comparison of predicted and measured 13C-label enrich­
m ent (mole percentage excess, MPE) in L-(ring 13 C6] phenyl alanine 
from control sera as analyzed by G C-M S with the O-TMS quinoxali­
nol derivative. Ammonia-CI and selected ion monitoring (SIM) of the 
quasi-molecular ions [MH]+ and IMH + 6]* appearing a t mlz 309 
and mlz 315 were used for m easurem ent (see Fig. 3, bottom). Means 
of triplicate samples are shown (SD are included in  the symbols). 
Dashed line, regression line (y = 0.998* + 0.153, n = 27, R  = 0.999). — 4
For experimental details, see M aterials and Methods.
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FIG . 4. (A) Time course of the increase in concentration and ,:,C 
enrichm ent in  L-valine in serum  of an overnight fasted healthy pro­
band after ora] loading with l- [1 -13C] valine (38 jumol/kg body wt). (B) 
Time course of label enrichm ent in L-leucine and the corresponding 2- 
oxo acid (KIC, 4-methyl-2-oxopentanoate) in the serum  of a MSUD 
patient w ith increased plasma levels of branched-chain compounds 
(leu, 0.43 mmol/liter; K3C, 0.34 mmol/liter) after ingestion of L-[l- 
l3C]leucine (38 /anol/kg body wt). Label enrichm ent in branched- 
chain compounds was determ ined by G C -M S analysis of the O-TMS 
quinoxalinol derivatives as detailed under M aterials and Methods,
our laboratory, the enzymic-chemical procedure is now 
routinely used for monitoring the time course of 13C 
enrichment in serum branched-chain compounds in 
stable isotope studies on the in vivo oxidation rates of 
branched-chain L-amino acids in healthy subjects and 
patients with maple syrup urine disease. Typical re­
sults from oral loading tests with l-13C-labeled L-valine 
and L-leucine are presented in Fig. 4. The outcome of 
these studies and the medical implications will be re­
ported elsewhere.
DISCUSSIO N
The present study concentrated on the examination 
of the use of L-amino acid dehydrogenases readily 
available from commercial sources for the selective en­
zymatic-chemical synthesis of quinoxaline derivatives
from 13C- or 2H-labeled L-amino acids from physiologi­
cal sources.
Irrespective of the GC-MS method used for mea­
surement of label enrichment, L-amino acid fractions 
are generally purified by cation-exchange chromatogra­
phy prior to derivatization. In the case of L-glutamate, 
rapid and careful separation from L-glutamine, nor­
mally present in vast excess in physiological samples, 
is required in order to avoid significant interferences 
from hydrolysis of the latter compound (26). We tried 
ion-exchange SPE columns for the purification of L- 
amino acids (primarily from interfering 2-oxo acids) 
and for the separation of glutamate. Recoveries (>90%) 
and separation efficiency (>99.5%) were comparable to 
published procedures (26-28).
Reportedly, the L-amino acid dehydrogenase activi­
ties applied exhibit more or less limited substrate speci­
ficities (29-31). Furthermore, the equilibrium constant 
for the oxidative deamination of amino acids is gener­
ally rather unfavorable (29,30). Nevertheless, under 
our incubation conditions, the L-amino acids in ques­
tion, L-alanine, L-glutamate, and L-phenyl alanine, and 
the group of branched-chain L-amino acids were con­
verted to the derived 2-oxo acids by the belonging dehy­
drogenase activities with sufficient specificity and in 
reasonable yields (>70%). The procedure reported here 
for L-glutamate may also be applied to the synthesis of 
L-glutamine-derived quinoxaline derivative, if L-gluta- 
mine in the glutamate-free amino acid fraction is con­
verted beforehand to L-glutamate by treatment with L- 
glutaminase (EC 3.5.1.2) (32).
Recovery of quinoxaline derivatives was variable and 
amounted to about 15 to 35% of the L-amino acid con­
tent in serum samples. With the L-amino acids studied, 
the most appreciable losses obviously occurred during 
derivatization of the sensitive 2-oxo acids in hydrochlo­
ric o-phenylenediamine solution. Decomposition of 
some 2-oxo acid (presumably by decarboxylation 
(23,24)) prior to quinoxaline formation was inevitable, 
although rather mild conditions were applied for deri­
vatization. The final yield of quinoxaline derivatives 
posed, however, no analytical problems. At least 
around 3 nmol was recovered from 0.2 ml serum, 
about 50-fold more than needed for sensitive GC-MS 
analysis.
For gas chromatographic separation of quinoxaline 
derivatives, silylation with BSTFA is the most widely 
used derivatization procedure. Using the branched-
chain quinoxaline derivatives, we performed some 
additional GC-MS studies with underivatized quinox-
FIG . 3. (Top) G C -M S analysis of the O-TMS quinoxalinol derivative of L-alanine (label 265) as obtained from a hum an serum  by enzymic- 
chemical synthesis (see M aterials and Methods for details). E l and expanded scan mode (40-600 amu) were used for detection. In the inset, 
the  m ass spectrum  as obtained in ammonia-CI mode is shown. (Bottom) G C-M S analysis of the O-TMS quinoxalinol derivative of l -  
phenylalanine as obtained from a L-[13C]phenylalanine (ring-13Cfl, 99%) spiked hum an serum  by enzymic-chemical synthesis (see M aterials 
and Methods for details), Ammonia-CI and SIM of the quasi-molecular ions (MH1+ and [MH + 61+ at mfz 309 (upper trace) and mlz 316 
(lower trace), respectively, were used for detection. For convenience, the mass spectrum (Cl mode) is included in the inset.
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alines and with A/,N-dimefchylformamide dimethyl ace- 
tal as a derivatization reagent according to Fernandes 
et aL (33). When checked on the OV-1 column at our 
disposal, separation was not as excellent as with 
O-TMS derivatives. The underivatized quinoxalines 
exhibited more unfavorable gas chromatographic prop­
erties and the simultaneous formation of N- and 0~ 
methyl derivatives (33) rendered separation of methyl 
derivatives more difficult (results not shown),
Due to favorable gas chromatographic properties and 
negligible fragmentation in the Cl mode (17-19), 0- 
TMS derivatives were used throughout in the present 
study for GC-MS analysis of amino acid-derived quin­
oxalines.
Various applications were tested in order to examine 
the usefulness of the enzymatic chemical procedure for 
quantification of label enrichment in L-amino acids. 
With O-TMS quinoxalinol derivatives as prepared 
from solutions of variably enriched L-[ring-13Ce]- 
phenylalanine and L-[l-13C]leucine, a good correlation 
between predicted and actually measured label enrich­
ment was obtained by GC-MS analysis using ammo-
nia-CI and SIM of the quasi-molecular ions [MH]+ and 
[MH + nV {n = number of 13C-Iabeled carbons). Fur­
thermore, measured I3C enrichments in solutions of L- 
[ring-13C6]phenylalanine were practically identical 
when a commonly employed N-acyl alkylester (N~ 
trifluoroacetyl n-propyl derivative) and the O-TMS 
quinoxalinol derivative were used for comparative GC- 
MS analysis.
Finally, the procedure was applied to monitor the
dilution of l3C-label in serum branched-chain L-amino 
acids after oral loading with L-[l-13C]valine and L-[l- 
13C)leucine in in vivo metabolic studies on whole-body 
oxidation of branched-chain compounds in probands
and patients with maple syrup urine disease. Due to 
the selective formation of branched-chain quinoxaline 
derivatives, only few compounds had to be separated 
chromatographically and one common GC-MS pro­
gram could be used for determination of label enrich­
ment in a L-amino and the derived 2-oxo acid. Addition­
ally, natural enrichment could be measured in each 
run, because all three branched-chain L-amino acids 
are converted to the quinoxaline derivatives and be­
cause no label exchange occurs between branched- 
chain L-amino acids in vivo,
This is especially useful in experiments with L-[l- 
13C]leucine, where an enriched and natural amount of 
13C-label can be determined simultaneously by SIM at 
mtz 276 ([MH + 1]+) and mlz 275 ([MHD in the chro­
matographic peak of the O-TMS quinoxalinol deriva­
tive of L-leucine/4-methyl-2-oxopentanoate and L-iso- 
leucine/3-methyl-2-oxopentanoate, respectively.
In conclusion, the present enzymic-chemical proce­
dure appears to be well suited to sensitive determina­
tion of 13C or 2H enrichment in a number of L-amino
acids. Expenditure for preparation of quinoxaline de­
rivatives from L-amino acids is comparable to that of 
the most frequently used N-acylation O-alkylation pro­
cedures. However, the present method is more selec­
tive, N-0-Silyl derivatives of amino acids are rather 
unstable and multiple reaction products may be formed
during derivatization (2,3). The O-TMS quinoxalinol 
derivatives are stable and exhibit most favorable GC- 
MS properties, especially when Cl mode is applied. 
There is no need for two different GC-MS programs 
when 13C- and 2H-label enrichment must be measured 
in the L-amino as well as the corresponding 2-oxo acid.
In addition, use of t3C-labeled O-TMS quinoxalinol 
derivatives is not restricted to GC-MS analysis. Ac­
cording to our recent experience from in vivo experi­
ments with labeled branched-chain L-amino acids, 
these compounds are also well suited to the determina­
tion of label enrichment by gas chromatography com­
bustion isotope ratio-mass spectrometry [(34), Meier- 
Augenstein, W.f and Schadewaldt, P., unpublished 
results].
In some cases, enzymatic conversion of L-amino to 
their corresponding 2-oxo acids and subsequent chemi­
cal decarboxylation (24) may also provide an applicable 
alternative to the ninhydrin method (35) which is now 
widely used for selective measurement of 13C enrich­
ment in the Cl-position of individual L-amino acids. 
Separation from interfering compounds is achieved by 
preparative GC in the latter and by enzyme specificity 
in the proposed procedure.
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